期刊
CANCER MANAGEMENT AND RESEARCH
卷 13, 期 -, 页码 7497-7503出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/CMAR.S330103
关键词
metastatic peritoneal carcinomatosis; NSCLC; EGFR; malignant ascites; peritoneal nodule; intraperitoneal dissemination
类别
Metastatic peritoneal carcinomatosis (MPC) is uncommon in NSCLC patients, and treatment interventions can significantly improve prognosis, especially for patients with driver oncogenes and good performance status, who tend to have longer overall survival.
Background: Metastatic peritoneal carcinomatosis (MPC) is not common in patients with non small cell lung cancer (NSCLC), and the clinical characteristics and treatment outcomes are still unclear. Patients and Methods: We recruited 46 NSCLC patients with MPC at Keio University and affiliated hospitals (Keio Lung Oncology Group) between January 2011 and December 2017, then retrospectively investigated their clinical characteristics and the impact of treatment interventions on their survival. Results: The profile of histological subtype was predominantly adenocarcinoma and 15 patients harbored driver oncogenes. Univariate and multivariate analysis demonstrated that performance status and the presence of a driver oncogene were significantly associated with the prolonged overall survival (OS). Regarding treatment, the median OS in the treatment group (9.3 months) was significantly longer than in the best supportive care group (1.3 months) (P < 0.0001). Conclusion: The prognosis of MPC in NSCLC patients who receive only the best supportive care is poor, but therapeutic intervention may improve prognosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据